medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-6-94-97medsovet-1892Research ArticleОнкоурологияOncourologyВОЗМОЖНОСТИ КОМБИНАЦИИ ДОЦЕТАКСЕЛА С АНДРОГЕННОЙ ДЕПРИВАЦИЕЙ ПРИ ИНИЦИАЛЬНОЙ ТЕРАПИИ ГОРМОНОЧУВСТВИТЕЛЬНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫPOSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCERГРИЦКЕВИЧА. А.GRITSKEVICHA. A.

к.м.н.

PhD in medicine

МИШУГИНС. В.MISHUGINS. V.

к.м.н.

PhD in medicine

РУСАКОВИ. Г.RUSAKOVI. G.

д.м.н., профессор

MD, Prof.

Научно-исследовательский институт им. А.В. Вишневского Минздрава РоссииРоссияVishnevsky Scientific and Research Institute of the Ministry of Health of RussiaRussian FederationГородская больница им. Д.Д. Плетнева Департамента здравоохранения г. МосквыРоссияPletnev Municipal Hospital of the Moscow Healthcare DepartmentRussian FederationМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал Национального медицинского исследовательского радиологического центра Минздрава РоссииРоссияHerzen Moscow Scientific Oncologic Institute -Affiliate of the National Medical Research Centre of the Ministry of Health of RussiaRussian Federation201719062017069497Copyright © ГРИЦКЕВИЧ А.А., МИШУГИН С.В., РУСАКОВ И.Г., 20172017ГРИЦКЕВИЧ А.А., МИШУГИН С.В., РУСАКОВ И.Г.GRITSKEVICH A.A., MISHUGIN S.V., RUSAKOV I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1892

Андрогенная депривационная терапия (АДТ) используется в лечении метастатического рака предстательной железы (РПЖ) со времени первого описания его гормональной зависимости в 1941 г. После получения результатов исследования ТАХ 327 в 2004 г. препарат из группы таксанов – доцетаксел стал основным цитостатическим агентом в лечении кастрационно-резистентного рака предстательной железы (КРРПЖ). В недавно опубликованном исследовании CHAARTED было впервые показано, что комбинация АДТ с доцетакселом у мужчин с гормоночувствительным метастатическим РПЖ (ГЧРПЖ) показала преимущество в общей выживаемости (ОВ) на 13,6 месяцев по сравнению с самостоятельной АДТ. Подобные результаты получены в исследовании STAMPEDE у мужчин с местно-распространенным и метастатическим РПЖ с инициальной длительной АДТ. Комбинация шести курсов доцетаксела с AДT у мужчин, начинающих долгосрочную AДT, продемонстрировала аналогичное преимущество ОВ по сравнению со стандартной АДТ на 10 месяцев. Основываясь на достоверности полученных результатов лечения новым сочетанием цитостатического и гормональных препаратов, доцетаксел в дополнение к AДT следует рассматривать как базовую инициальную терапию для мужчин с впервые выявленным гормоночувствительным РПЖ, что отражено в практических рекомендациях по лекарственному лечению злокачественных опухолей (RUSSCO) 2016 г. и рекомендациях Европейской ассоциации урологов 2017 г.

Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer metastatic cancer (PC) since the first description of its hormone dependence in 1941. After receiving the results of a TAX 327 study in 2004, the drug from the taxanes - docetaxel became the main cytostatic agent in the treatment of the castration resistant prostate cancer (CRPC). In a recently publishedstudy CHAARTED it was shown for the first time that the combination of ADT with docetaxel in men with hormone-sensitive metastatic prostate cancer (HSMPC) showed the advantage in the total survival rate by 13.6 months compared to the independent ADT. Similar results were obtained in the STAMPEDE study of men with local-distrubuted and metastatic PC with initial long ADT. A combination of six docetaxel courses with ADT in men starting long-term ADT demonstrated the same advantage by the survival rate parameter compared to the standard ADT by 10 months. Based on the reliability of the treatment results obtained by a new combination of a cytostatic and hormonal product, docetaxel in addition to ADT should be regarded as the basic initial therapy for men with the first identified hormone-sensitive PC, as reflected in the practical recommendations on the treatment of malignant tumours (RUSSCO) 2016 and the recommendations of the European Association of Urologists, 2017.

доцетакселгормоночувствительный рак предстательной железытаксаныметастатический рак предстательной железыdocetaxelhormone-sensitive prostate cancertaxanesprostate gland metastatic cancerReferencesЗлокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой М., 2017. С.12-36.Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой М., 2017. С.12-36.Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-20.Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-20.Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502–12.Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502–12.Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008, 26(2): 242–5.Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008, 26(2): 242–5.Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol, 2014, 66(4): 646-52.Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol, 2014, 66(4): 646-52.van Soest RJ, de Morree ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration- resistant prostate cancer. Eur Urol, 2015, 67(6): 981-5.van Soest RJ, de Morree ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration- resistant prostate cancer. Eur Urol, 2015, 67(6): 981-5.van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross- resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castrationresistant prostate cancer. Eur J Cancer, 2013, 49(18): 3821-30.van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross- resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castrationresistant prostate cancer. Eur J Cancer, 2013, 49(18): 3821-30.Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med, 2015, 373(8): 737-46.Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med, 2015, 373(8): 737-46.James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley D, Spears MR, et al. Adding docetaxel and/or zoledronic acid for hormone-naive prostate cancer (STAMPEDE): survival results form an adaptive multi-arm multi-stage platform randomised controlled trial. Lancet, 2016, 387(10024): 1163-77.James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley D, Spears MR, et al. Adding docetaxel and/or zoledronic acid for hormone-naive prostate cancer (STAMPEDE): survival results form an adaptive multi-arm multi-stage platform randomised controlled trial. Lancet, 2016, 387(10024): 1163-77.Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Adding docetaxel or bisphosphonates to standard-of-care in men with localised or metastatic hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol, 2016, 17(2): 243-56.Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Adding docetaxel or bisphosphonates to standard-of-care in men with localised or metastatic hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol, 2016, 17(2): 243-56.Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol, 2010, 28(30): 4562–7.Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol, 2010, 28(30): 4562–7.Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengelov L. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration- resistant prostate cancer: Is there a clinical benefit? Urol Oncol, 2015, 33(11): 494.Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengelov L. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration- resistant prostate cancer: Is there a clinical benefit? Urol Oncol, 2015, 33(11): 494.Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castrationresistant prostate cancer (ELM-PC 4): a doubleblind, multicentre, phase 3, randomised, placebo- controlled trial. Lancet Oncol, 2015, 16(3): 338-48.Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castrationresistant prostate cancer (ELM-PC 4): a doubleblind, multicentre, phase 3, randomised, placebo- controlled trial. Lancet Oncol, 2015, 16(3): 338-48.

The authors declare that there are no conflicts of interest present.